| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-05-13 |
| タイトル |
|
|
タイトル |
Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3 |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
liver stiffness |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
MASLD |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
pemafibrate |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Ichikawa, Tatsuki
Yamashima, Mio
Yamamichi, Shinobu
Koike, Makiko
Nakano, Yusuke
Yajima, Hiroyuki
Miyazaki, Osamu
Ikeda, Tomonari
Okamura, Takuma
Komatsu, Naohiro
Sugio, Sayuri
Yoshino, Miruki
Miyaaki, Hisamitsu
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Objective: To evaluate the effect of pemafibrate (PEM) on metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: We retrospectively evaluated 43 patients with hyperlipidemia and MASLD to determine changes in clinical factors between the start of PEM treatment and 0.5 years later. Using FibroScan, 39 of 43 patients were evaluated for liver stiffness (LS; kPa) and controlled attenuation parameter (CAP; dB/m). None of the patients had decompensated cirrhosis. Results: Thirty patients were women, the median age was 66 years old, the median fibrosis-4 (FIB-4) score was 2.52, the median LS was 8.05 kPa, and the median CAP was 280.5 dB/m at the start of PEM treatment. AST, ALT, ALP, γGTP, and triglyceride levels decreased 0.5 years after starting PEM treatment, but FIB-4, LS, and CAP values did not decrease. However, LS decreased in patients with a FIB-4 index ≥1.3 at the start of PEM treatment, whereas it did not change in patients with a FIB-4 index <1.3. Similarly, LS decreased in patients with a value ≥8 kPa at the start of treatment and did not change in those with <8 kPa. The decreased LS group had higher baseline ALT and LS levels and lower ALT levels during 0.5 years of follow-up than the increased LS group. Conclusion: At the initiation of PEM treatment, the LS decreased in patients with MASLD complicated by hyperlipidemia and moderate LS (FIB-4>1.3 or LS >8 kPa). Although there is currently no approved treatment for MASLD, PEM may be a viable treatment option for MASLD with mild LS. |
|
言語 |
en |
| 書誌情報 |
en : Internal Medicine
巻 64,
号 9,
p. 1296-1302,
発行日 2025-05-01
|
| 出版者 |
|
|
出版者 |
Japanese Society of Internal Medicine |
|
言語 |
en |
| 出版社別言語 |
|
|
言語 |
ja |
|
値 |
日本内科学会 |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0918-2918 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.2169/internalmedicine.4337-24 |
| 権利 |
|
|
権利情報 |
© 2025 The Japanese Society of Internal Medicine This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license. https://creativecommons.org/licenses/by-nc-nd/4.0/ |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Internal Medicine, 64(9), pp.1296-1302; 2025 |
|
言語 |
en |
IM64_1296.pdf (187 KB)
